189 results
8-K
NVTAQ
Invitae Corp
22 Jan 24
Invitae Completes Sale of Reproductive Health Assets to Natera
7:05am
to Invitae and (ii) will make additional payments up to $42.5 million, which amount, if any, includes (a) the payment of cash and/or providing litigation … disposing of all claims in respect of the Natera v. ArcherDx Case, Natera will provide to the Company cash and/or litigation-related credits, if any
8-K
EX-99.1
NVTAQ
Invitae Corp
22 Sep 23
Invitae Receives Notice of Non-Compliance with NYSE
5:02pm
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating … relationships; the company's ability to compete; risks associated with litigation; the company's ability to use rapidly changing genetic data
8-K
EX-99.2
NVTAQ
Invitae Corp
7 Sep 21
Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research
8:01am
statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s beliefs regarding … or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing
8-K
NVTAQ
Invitae Corp
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding … to increase demand for its tests; the Company’s ability to drive revenue; the impact of current and future litigation on the Company’s business
8-K
EX-99.1
NVTAQ
Invitae Corp
22 Jan 24
Invitae Completes Sale of Reproductive Health Assets to Natera
7:05am
screening, to Natera (NASDAQ: NTRA).
The value of the transaction is up to $52.5 million, including cash, milestone payments and litigation credits. Natera … of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's strategic objectives and anticipated outcomes
8-K
EX-99.1
6f6ceh o59e9
20 Dec 22
Other Events
9:00am
8-K
EX-99.1
psd7q i9h
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K
EX-10.4
cogthmnatf
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
EX-99.1
jsxsyh8pfny
11 Jan 22
Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million
4:20pm
8-K
EX-99.1
f3s9gg9
14 Feb 24
Entry into a Material Definitive Agreement
6:59am
8-K
EX-99.2
ueawefp80
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K
EX-10.3
smma0y1csrih
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.1
eouoz5d9
18 Jul 22
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow
9:28pm
8-K
9gr 3muhyukzpf
2 May 24
Entry into a Material Definitive Agreement
4:39pm
8-K
EX-99.1
0vk8z0prmo0r1y6
6 Apr 20
Invitae Announces Pricing of Public Offering of Common Stock
5:00pm
8-K
j5sx 06ij40jvcp
14 Feb 24
Entry into a Material Definitive Agreement
6:59am
8-K
EX-99.1
0faw9
4 Sep 19
Invitae Announces Proposed Offering of $200 Million of Convertible Senior Notes
4:54pm
8-K
EX-99.1
j83oil3wtqlm
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
k3vwnc5cm0kkf8xc6h
6 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:07pm
8-K
EX-99.2
zhh1ii
18 Jul 22
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow
9:28pm